[ Pobierz całość w formacie PDF ]

novel mechanofusion system.
2008. Co-spray-dried unfractionated heparin with
In vitro measurements performed on both
L-leucine as a dry powder inhaler mucolytic for
processed and unprocessed salbutamol sulphate
cystic fibrosis therapy. J Pharm Sci 97:4857
indicated significant improvements in aerosolisa-
4868.
tion by mechanofusing an FCA with the drug
9. Tee SK, Marriott C, Zeng XM, Martin GP. 2000. The
particles. By physically disrupting the drug
use of different sugars as fine and coarse carriers for
interparticle interactions, this formulation strat-
aerosolised salbutamol sulphate. Int J Pharm 208:
egy enabled deagglomeration of the cohesive 111 123.
10. Steckel H, Bolzen N. 2004. Alternative sugars as
particles. For budesonide, although a smaller
potential carriers for dry powder inhalations. Int J
variation was observed in %FPF, a net decrease in
Pharm 270:297 306.
device retention due to a reduction in powder bed
11. Hooton JC, Jones MD, Price R. 2006. Predicting the
strength contributed to significantly increase the
behavior of novel sugar carriers for dry powder
drug respirable fraction.30
inhaler formulations via the use of a cohesive-adhe-
Aerosolisation analyses performed on the air-
sive force balance approach. J Pharm Sci 95:1288
borne powders using a Spraytec1 system revealed
1297.
dramatic variations in rate of particle emission,
12. Louey MD, Van Oort M, Hickey AJ. 2004. Aerosol
upon device actuation, between treated and
dispersion of respirable particles in narrow size
untreated drug particles. The anti-adherent
distributions using drug-alone and lactose-blend
and/or anti-friction aptitudes of the FCAs seemed formulations. Pharm Res 21:1207 1213.
to generate effective aerosolisation of the carrier- 13. Clarke MJ, Tobyn MJ, Staniforth JN. 2001. The
formulation of powder inhalation systems contain-
free formulations, especially with the use of both
ing a high mass of nedocromil sodium trihydrate.
lecithin and MgSt. A considerable time reduction
J Pharm Sci 90:213 223.
in powder bed fluidisation and increased entrain-
14. Edwards AM, Chambers A. 1989. Comparison of a
ment efficiency was also observed via the laser
lactose-free formulation of sodium cromoglycate
diffraction studies.
and sodium cromoglycate plus lactose in the treat-
In summary, significantly improved deagglo-
ment of asthma. Curr Med Res Opin 11:283 292.
meration and entrainment of both drugs was
15. Adi H, Traini D, Chan HK, Young PM. 2008. The
achieved by selecting a FCA in conjunction with a
influence of drug morphology on the aerosolisation
mixing procedure capable of producing a surface
efficiency of dry powder inhaler formulations.
coating of the FCA. J Pharm Sci 97:2780 2788.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 98, NO. 8, AUGUST 2009 DOI 10.1002/jps
ROLE OF FCAs IN HIGH DOSE DRY POWDER INHALER FORMULATIONS 2783
16. Edwards DA, Hanes J, Caponetti G, Hrkach J, containing magnesium stearate (WO IPO 0243702
BenJebria A, Eskew ML, Mintzes J, Deaver D, A2), pp. 1-11.
Lotan N, Langer R. 1997. Large porous particles 24. Begat P, Price R, Harris H, Morton DAV, Staniforth
for pulmonary drug delivery. Science 276:1868 JN. 2005. The influence of force control agents on
1871. the cohesive-adhesive balance in dry powder inha-
17. Vanbever R, Mintzes JD, Wang J, Nice J, Chen DH, ler formulations. KONA Powder Part 23:109 121.
Batycky R, Langer R, Edwards DA. 1999. Formula- 25. Morton DAV. 2008. Dry powder inhaler formula-
tion and physical characterization of large porous tions comprising of surface-modified particles with
particles for inhalation. Pharm Res 16:1735 anti-adherent additives (US 2008/0127972 A1),
1742. pp. 1 7.
18. Schiavone H, Palakodaty S, Clark A, York P, Tzan- 26. Hooton JC, Jones MD, Harris H, Shur J, Price R.
nis ST. 2004. Evaluation of SCF-engineered parti- in press. The influence of crystal habit on the
cle-based lactose blends in passive dry powder prediction of dry powder inhalation formulation
inhalers. Int J Pharm 281:55 66. performance using the cohesive-adhesive balance
19. Briggner LE, Buckton G, Bystrom K, Darcy P. 1994. approach. Drug Dev Ind Pharm.
The use of isothermal microcalorimetry in the study 27. Young PM, Price R. 2004. The influence of humidity
of changes in crystallinity induced during the pro- on the aerosolisation of micronised and SEDS pro-
cessing of powders. Int J Pharm 105:125 135. duced salbutamol sulphate. Eur J Pharm Sci
20. Shekunov BY, Feeley JC, Chow AHL, Tong HHY, 22:235 240.
York P. 2003. Aerosolisation behaviour of micro- 28. Dickhoff BHJ, Ellison MJH, de Boer AH, Frijlink
nised and supercritically-processed powders. HW. 2002. The effect of budesonide particle mass on
J Aerosol Sci 34:553 568. drug particle detachment from carrier crystals in
21. Palakodaty S, York P, Pritchard J. 1998. Super- adhesive mixtures during inhalation. Eur J Pharm
critical fluid processing of materials from aqueous Biopharm 54:245 248.
solutions: The application of SEDS to lactose as a 29. Begat P, Morton DAV, Staniforth JN, Price R. 2004.
model substance. Pharm Res 15:1835 1843. The cohesive-adhesive balances in dry powder inha-
22. Tormoen GW, Drelich J, Beach ER. 2004. Analysis ler formulations. I: Direct quantification by atomic
of atomic force microscope pull-off forces for gold force microscopy. Pharm Res 21:1591 1597.
surfaces portraying nanoscale roughness and spe- 30. Shur J, Harris H, Jones MD, Kaerger JS, Price R.
cific chemical functionality. J Adhes Sci Technol 2008. The role of fines in the modification of the
18:1 17. fluidization and dispersion mechanism within dry
23. Staniforth JN, Harris H, Morton DAV, Bannister R. powder inhaler formulations. Pharm Res 25:1931
2002. Pharmaceutical compositions for inhalation 1940.
DOI 10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 98, NO. 8, AUGUST 2009 [ Pobierz całość w formacie PDF ]